AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19458887 — intervention group
Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 42
Study 17502530 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus 400 IU of cholecalciferol (vitamin D) daily
Number of subjects: 36282
Study 17502530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36282
Study 12804729 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin ER 1,000 mg/day
Number of subjects: 60
Study 12804729 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin ER 2,000 mg/day
Number of subjects: 60
Study 12804729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12804729 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin ER (both dosages)
Number of subjects: 60
Study 10744847 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal stress manipulation
Number of subjects: 82
Study 10744847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ego-related stress manipulation 1
Number of subjects: 82
Study 10744847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ego-related stress manipulation 2
Number of subjects: 82
Study 10744847 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study 9010511 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutional AIDS prevention program
Number of subjects: 0
Study 9010511 — intervention group
Group type: COMPARATOR
Intervention: Control campus
Number of subjects: 0
Study 1354938 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine (100 mg, 3 times daily)
Number of subjects: 25
Study 1354938 — intervention group
Group type: COMPARATOR
Intervention: Ibopamine (acute administration)
Number of subjects: 25
Study 1354938 — intervention group
Group type: COMPARATOR
Intervention: Ibopamine (chronic administration)
Number of subjects: 25
Study 1354938 — intervention group
Group type: COMPARATOR
Intervention: Ibopamine (acute and chronic administration)
Number of subjects: 25
Study 1354938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 6423720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol infusion (0.4 g/kg)
Number of subjects: 19
Study 6423720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol infusion (0.8 g/kg)
Number of subjects: 19
Study 6423720 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 19
Study 30969797 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (120 mg)
Number of subjects: 0
Study 30969797 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid (ZA)
Number of subjects: 0
Study 28190794 — intervention group
Group type: EXPERIMENTAL
Intervention: BMSC (n = 17)
Number of subjects: 53
Study 28190794 — intervention group
Group type: EXPERIMENTAL
Intervention: BMMC (n = 16)
Number of subjects: 53
Study 28190794 — intervention group
Group type: COMPARATOR
Intervention: CTRL (n = 20)
Number of subjects: 53
Study 25499546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (retinol palmitate 50,000 IU plus vitamin E 95-126 IU)
Number of subjects: 44984
Study 25499546 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin E 95-126 IU)
Number of subjects: 44984
Study 23820354 — intervention group
Group type: EXPERIMENTAL
Intervention: High fluid intake
Number of subjects: 40
Study 23820354 — intervention group
Group type: COMPARATOR
Intervention: Low fluid intake (dehydrated, 1-3% weight loss)
Number of subjects: 40
Study 21659667 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal priming of exercise self-regulatory efficacy beliefs
Number of subjects: 0
Study 21659667 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraliminal priming of exercise self-regulatory efficacy beliefs
Number of subjects: 0
Study 21659667 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy priming
Number of subjects: 0
Study 21659667 — intervention group
Group type: COMPARATOR
Intervention: Control prime
Number of subjects: 0
Study 20141705 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU augmented with brief group cognitive therapy (CT)
Number of subjects: 172
Study 20141705 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 172
Study 16683683 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert (Jeneric/Pentron) resin composite with a flowable composite liner
Number of subjects: 50
Study 16683683 — intervention group
Group type: EXPERIMENTAL
Intervention: SureFil (Dentsply/Caulk) resin composite with a flowable composite liner
Number of subjects: 50
Study 16683683 — intervention group
Group type: COMPARATOR
Intervention: Alert (Jeneric/Pentron) resin composite
Number of subjects: 50
Study 16683683 — intervention group
Group type: COMPARATOR
Intervention: SureFil (Dentsply/Caulk) resin composite
Number of subjects: 50
Study 17205408 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual colonoscopy
Number of subjects: 48
Study 10230944 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver in supine position
Number of subjects: 50
Study 10230944 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver in Trendelenburg position
Number of subjects: 50
Study 10230944 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Valsalva maneuver and Trendelenburg position
Number of subjects: 50
Study 10230944 — intervention group
Group type: COMPARATOR
Intervention: LIJV CSA less than RIJV
Number of subjects: 50
Study 8688398 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose ritodrine infusion
Number of subjects: 203
Study 8688398 — intervention group
Group type: COMPARATOR
Intervention: Conventional schedule of increasing doses of ritodrine
Number of subjects: 203
Study 2070984 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.5 mg)
Number of subjects: 77
Study 2070984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 6409009 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC and 5‐FU (Group A)
Number of subjects: 94
Study 6409009 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC, 5‐FU and OK‐432 (Group B)
Number of subjects: 94
Study 6409009 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 94
Study 30761568 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy (PT)
Number of subjects: 82
Study 30761568 — intervention group
Group type: COMPARATOR
Intervention: One session of plaque removal (Control group)
Number of subjects: 82
Study 30077955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Insomnia (CBT-I)
Number of subjects: 74
Study 27390130 — intervention group
Group type: EXPERIMENTAL
Intervention: IV→150 mg secukinumab
Number of subjects: 371
Study 27390130 — intervention group
Group type: EXPERIMENTAL
Intervention: IV→75 mg secukinumab
Number of subjects: 371
Study 27390130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study 24162898 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) group
Number of subjects: 216
Study 21104100 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanofilled resin composite with intermediary layer of flowable resin composite
Number of subjects: 48
Study 21104100 — intervention group
Group type: COMPARATOR
Intervention: Nanofilled resin composite without intermediary layer of flowable resin composite
Number of subjects: 48
Study 20554627 — intervention group
Group type: EXPERIMENTAL
Intervention: CLU (rs11136000)
Number of subjects: 1829
Study 18605891 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment
Number of subjects: 18
Study 18605891 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical therapy
Number of subjects: 18
Study 15750038 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with OSAS
Number of subjects: 10
Study 15750038 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 10
Study 12219856 — intervention group
Group type: EXPERIMENTAL
Intervention: Accountability (expectation to explain, justify, and defend one's self-evaluations to an audience)
Number of subjects: 0
Study 12219856 — intervention group
Group type: EXPERIMENTAL
Intervention: Accountability (as defined above)
Number of subjects: 0
Study 10505301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 400 micrograms/day
Number of subjects: 349
Study 10505301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 300 micrograms/day
Number of subjects: 349
Study 10505301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349
Study 10505301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin treatment
Number of subjects: 349
Study 8572787 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling jacket
Number of subjects: 20
Study 8572787 — intervention group
Group type: COMPARATOR
Intervention: Stanford method (saline lavage)
Number of subjects: 20
Study 2012456 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg of aspirin with 64 mg of caffeine
Number of subjects: 207
Study 2012456 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg of aspirin
Number of subjects: 207
Study 2012456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 30632140 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg
Number of subjects: 997
Study 30632140 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab 45 mg or 90 mg
Number of subjects: 997
Study 30632140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 997
Study 28787712 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate feedback regarding amyloid status
Number of subjects: 618
Study 28787712 — intervention group
Group type: COMPARATOR
Intervention: Delayed feedback regarding amyloid status
Number of subjects: 618
Study 25391306 — intervention group
Group type: EXPERIMENTAL
Intervention: HP + CVVH
Number of subjects: 684
Study 25391306 — intervention group
Group type: COMPARATOR
Intervention: HP
Number of subjects: 684
Study 23497560 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape Up-LD intervention (12 weekly sessions including healthy eating messages, advice on physical activity, and behaviour change techniques)
Number of subjects: 60
Study 23497560 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study 21803749 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping NSAIDs (for a minimum of 5 drug half-lives)
Number of subjects: 58
Study 21803749 — intervention group
Group type: COMPARATOR
Intervention: Continuing NSAIDs
Number of subjects: 58
Study 18976782 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine-treated schizophrenia patients
Number of subjects: 163
Study 18976782 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmedicated schizophrenia patients
Number of subjects: 163
Study 17313721 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate milk (500 ml, 900 kJ)
Number of subjects: 22
Study 17313721 — intervention group
Group type: COMPARATOR
Intervention: Cola (500 ml, 900 kJ)
Number of subjects: 22
Study 17313721 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate milk
Number of subjects: 22
Study 17313721 — intervention group
Group type: COMPARATOR
Intervention: Cola
Number of subjects: 22
Study 17313721 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate milk and Cola
Number of subjects: 22
Study 15369934 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive antiemetic therapy
Number of subjects: 25
Study 15369934 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pre-emptive therapy)
Number of subjects: 25
Study 11394392 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of enamel matrix proteins (EMP), bovine porous bone mineral (BPBM), and a bioabsorbable membrane for guided tissue regeneration (GTR)
Number of subjects: 18
Study 11394392 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 18
Study 9721382 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires measuring condom use (varied types)
Number of subjects: 2269
Study 9721382 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week coital logs or past 10 acts
Number of subjects: 2269
Study 9721382 — intervention group
Group type: EXPERIMENTAL
Intervention: Always-to-never scales
Number of subjects: 2269
Study 9721382 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal consistency of responses
Number of subjects: 2269
Study 9721382 — intervention group
Group type: EXPERIMENTAL
Intervention: Future studies
Number of subjects: 2269
Study 8055123 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical activity (PA) level in women
Number of subjects: 339
Study 8055123 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical activity (PA) level in men
Number of subjects: 339
Study 8055123 — intervention group
Group type: COMPARATOR
Intervention: Control group (no radiologic evidence of knee OA)
Number of subjects: 339
Study 2500361 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 4 x 0.1 mg.day‐1
Number of subjects: 22
Study 2500361 — intervention group
Group type: COMPARATOR
Intervention: Inhaled cromoglycate 4 x 2 mg.day‐1
Number of subjects: 22
Study 31240435 — intervention group
Group type: EXPERIMENTAL
Intervention: First-degree relatives (FDRs) of probands with PC
Number of subjects: 4095
Study 31240435 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-degree relatives (SDRs) of probands with PC
Number of subjects: 4095
Study 31240435 — intervention group
Group type: EXPERIMENTAL
Intervention: First cousins (FCs) of probands with PC
Number of subjects: 4095
Study 31240435 — intervention group
Group type: EXPERIMENTAL
Intervention: First-degree relatives (FDRs) of female probands with PC
Number of subjects: 4095
Study 31240435 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-degree relatives (SDRs) of female probands with PC
Number of subjects: 4095
Study 31240435 — intervention group
Group type: EXPERIMENTAL
Intervention: First cousins (FCs) of female probands with PC
Number of subjects: 4095
Study 31240435 — intervention group
Group type: EXPERIMENTAL
Intervention: First-degree relatives (FDRs) of probands diagnosed at age < 65 years
Number of subjects: 4095
Study 31240435 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-degree relatives (SDRs) of probands diagnosed at age < 65 years
Number of subjects: 4095
Study 31240435 — intervention group
Group type: EXPERIMENTAL
Intervention: First cousins (FCs) of probands diagnosed at age < 65 years
Number of subjects: 4095
Study 28427872 — intervention group
Group type: EXPERIMENTAL
Intervention: Abduction brace
Number of subjects: 0
Study 28427872 — intervention group
Group type: COMPARATOR
Intervention: Antirotation sling
Number of subjects: 0
Study 28427872 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 25583616 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized care
Number of subjects: 556
Study 25583616 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 556
Study 23646465 — intervention group
Group type: EXPERIMENTAL
Intervention: Xingpi Yang'er Granule (XYG)
Number of subjects: 120
Study 23646465 — intervention group
Group type: COMPARATOR
Intervention: Live Combined Bifidobacterium and Lactobacillus Tablets (Control)
Number of subjects: 120
Study 21592337 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction ratings after individual primary care consultations
Number of subjects: 0
Study 21592337 — intervention group
Group type: COMPARATOR
Intervention: Physician satisfaction ratings after individual primary care consultations
Number of subjects: 0
Study 18377970 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Schools! BC intervention (INT)
Number of subjects: 268
Study 18377970 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (UP)
Number of subjects: 268
Study 17137211 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg once daily for 24 weeks)
Number of subjects: 43
Study 17137211 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 mg once daily for 24 weeks)
Number of subjects: 43
Study 14594113 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (7 participants)
Number of subjects: 14
Study 14594113 — intervention group
Group type: COMPARATOR
Intervention: Placebo (7 participants)
Number of subjects: 14
Study 11003445 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen-specific immunotherapy with birch pollen extract
Number of subjects: 52
Study 11003445 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen-specific immunotherapy with grass pollen extract
Number of subjects: 52
Study 8622574 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol 10 mg orally
Number of subjects: 53
Study 8622574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 8622574 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stress (Trier Social Stress Test)
Number of subjects: 53
Study 1315685 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg repirinast
Number of subjects: 12
Study 1315685 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg repirinast
Number of subjects: 12
Study 1315685 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg repirinast
Number of subjects: 12
Study 3908675 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoprofen calcium, 200 mg
Number of subjects: 85
Study 3908675 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoprofen calcium, 400 mg
Number of subjects: 85
Study 3908675 — intervention group
Group type: COMPARATOR
Intervention: aspirin, 650 mg
Number of subjects: 85
Study 3908675 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 85
Study 31081596 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent sleep intervention
Number of subjects: 33
Study 31081596 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 33
Study 28734107 — intervention group
Group type: EXPERIMENTAL
Intervention: XRNTX 380 mg administered by gluteal injection at 4-week intervals (n=50)
Number of subjects: 100
Study 28734107 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo administered by gluteal injection at 4-week intervals (n=50)
Number of subjects: 100
Study 28734107 — intervention group
Group type: EXPERIMENTAL
Intervention: XRNTX 380 mg
Number of subjects: 100
Study 28734107 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 100
Study 26569149 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine (1‐3 mg/24 h)
Number of subjects: 150
Study 26569149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 24764585 — intervention group
Group type: EXPERIMENTAL
Intervention: Black raspberries (BRBs) - daily for 9 months, including BRB powder orally and two BRB suppositories at bedtime
Number of subjects: 14
Study 24764585 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo plus BRB suppositories
Number of subjects: 14
Study 24764585 — intervention group
Group type: EXPERIMENTAL
Intervention: Black raspberries (BRBs) - daily for 9 months
Number of subjects: 14
Study 22613648 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacotrabeculectomy
Number of subjects: 31
Study 22613648 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 31
Study 20569707 — intervention group
Group type: COMPARATOR
Intervention: Baseline Troponin T levels (undetectable)
Number of subjects: 1250
Study 20569707 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Troponin T levels (detectable but below median)
Number of subjects: 1250
Study 20569707 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Troponin T levels (above median)
Number of subjects: 1250
Study 20569707 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of baseline TnT and ST-segment resolution (STRes)
Number of subjects: 1250
Study 18313505 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen
Number of subjects: 0
Study 18313505 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 18313505 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 18313505 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 18313505 — intervention group
Group type: COMPARATOR
Intervention: Other agents
Number of subjects: 0
Study 15894560 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-Lipuro (3 mg/kg)
Number of subjects: 83
Study 15894560 — intervention group
Group type: COMPARATOR
Intervention: Diprivan with added lidocaine (0.3 mg/kg)
Number of subjects: 83
Study 11999563 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 64
Study 11999563 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 64
Study 9809085 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg‐1
Number of subjects: 135
Study 9809085 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg‐1 plus dexamethasone 8 mg i.v.
Number of subjects: 135
Study 9809085 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 135
Study 7698516 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 31
Study 2676966 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methylphenidate
Number of subjects: 24
Study 2676966 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 665535 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine therapy
Number of subjects: 20
Study 665535 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after 3 days of therapy and again after 30 days)
Number of subjects: 20
Study 30383467 — intervention group
Group type: EXPERIMENTAL
Intervention: IRD scale (intervention)
Number of subjects: 2380
Study 30290667 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol total intravenous anesthesia
Number of subjects: 84
Study 30290667 — intervention group
Group type: COMPARATOR
Intervention: Desflurane inhalation anesthesia
Number of subjects: 84
Study 26828395 — intervention group
Group type: EXPERIMENTAL
Intervention: Character strengths‐based intervention using the Values in Action Inventory of Strengths for Youth
Number of subjects: 81
Study 26828395 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 81
Study 24754350 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT/A treatment (230 or 460 U onabotulinumtoxinA)
Number of subjects: 52